An Innovative Protein Degrader Targeting STAT3 Receives FDA Orphan Drug Designation

Kymera Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its investigational protein degrader KT-333 for the treatment of peripheral T-cell lymphoma (PTCL). KT-333 is a potential "first-in-class" protein degrader that degrades the transcriptional regulator STAT3. STAT3 is one of the key regulators of PTCL, and no therapy targeting this signaling pathway is currently approved for the treatment of PTCL.

STAT3 is a transcription factor that can be activated by different cytokine and growth factor receptors, possibly also by mutations in oncogenic fusion proteins and STAT3 itself. It has multiple roles in promoting tumor growth and metastasis. Overactive STAT3 has long been considered a "non-druggable" target, and targeting protein degradation provides a new strategy to address the "non-druggable" nature of this target.

KT-333 has resulted in complete and durable tumor regression in various preclinical tumor models. It is currently being evaluated in a Phase 1 clinical trial for the treatment of patients with relapsed/refractory blood cancers and solid tumors, including aggressive lymphomas.

"This orphan drug designation demonstrates the potential of protein degraders targeting STAT3, which has historically been considered undruggable, to revolutionize the treatment of PTCL," said Kymera co-founder and CEO Dr. Nello Mainolfi. "We look forward to collaborating with The lymphoma patient population is collaborating to rapidly advance KT-333 as a potential therapy for PTCL and to expand clinical studies of this innovative mechanism of protein degradation in hematology and solid tumors."